Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with…
Continue Reading-
Abliva Achieves Important Milestone in the Ongoing FALCON Study
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare…
Continue Reading -
Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation
Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation Abliva AB (Nasdaq Stockholm: ABLI) a…
Continue Reading -
ARTHEX BIOTECH
Arthex Biotech is a Spanish biopharmaceutical company developing advanced RNA treatments...
Continue Reading -
ARTHEx Biotech Announces Closing of €42 M Series B Financing
ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel…
Continue Reading -
COMPLEMENT THERAPEUTICS
Complement Therapeutics GmbH is a German headquartered biotechnology company...
Continue Reading -
Complement Therapeutics Secures €72 Million in Series A Financing
Complement Therapeutics Secures €72 Million in Series A Financing...
Continue Reading -
Alex Therapeutics extends financing round to €4.75M with leading life science VC
Innovestor Life Science, a leading biotech and digital health VC, invests €1.25M in the digital…
Continue Reading -
Alex Therapeutics and Vicore Pharma today announce the first study subject enrolled in the pivotal study COMPANION evaluating Almee™
Stockholm, 5th December 2022 — Alex Therapeutics and Vicore Pharma today announce the first study…
Continue Reading -
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in…
Continue Reading